CL2009000986A1 - Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma - Google Patents
Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucomaInfo
- Publication number
- CL2009000986A1 CL2009000986A1 CL2009000986A CL2009000986A CL2009000986A1 CL 2009000986 A1 CL2009000986 A1 CL 2009000986A1 CL 2009000986 A CL2009000986 A CL 2009000986A CL 2009000986 A CL2009000986 A CL 2009000986A CL 2009000986 A1 CL2009000986 A1 CL 2009000986A1
- Authority
- CL
- Chile
- Prior art keywords
- pai
- glaucoma
- inhibitors
- preparation
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Método para tratar el glaucoma o iop elevada que comprende la utilización de una cantidad eficaz de una composición que comprende un agente que inhibe la expresión o la actividad de pai-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4817608P | 2008-04-26 | 2008-04-26 | |
US12/421,456 US20090202524A1 (en) | 2007-10-31 | 2009-04-09 | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000986A1 true CL2009000986A1 (es) | 2010-12-31 |
Family
ID=40810596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000986A CL2009000986A1 (es) | 2008-04-26 | 2009-04-24 | Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma |
Country Status (10)
Country | Link |
---|---|
US (2) | US20090202524A1 (es) |
EP (1) | EP2296647A2 (es) |
JP (1) | JP2011518828A (es) |
KR (1) | KR20100135953A (es) |
CN (1) | CN102046168A (es) |
AR (1) | AR071393A1 (es) |
CL (1) | CL2009000986A1 (es) |
TW (1) | TW200946113A (es) |
UY (1) | UY31786A1 (es) |
WO (1) | WO2009131850A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602005008935D1 (de) * | 2004-04-26 | 2008-09-25 | Alcon Inc | Statine zur behandlung von okularer hypertonie und glaukom |
US10946076B2 (en) * | 2013-02-13 | 2021-03-16 | The Research Foundation For The State University Of New York | Glaucoma treatment |
SG10201710013RA (en) | 2013-08-13 | 2018-01-30 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
EP3069732B1 (en) * | 2013-11-14 | 2023-07-12 | The Doshisha | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage |
EP3381472A4 (en) | 2015-12-24 | 2019-07-31 | The Doshisha | MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4214215A1 (de) * | 1992-04-30 | 1993-11-04 | Behringwerke Ag | Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen |
AU771635B2 (en) * | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
DK1397130T3 (da) * | 2001-06-20 | 2007-11-12 | Wyeth Corp | Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1) |
JP2005523928A (ja) * | 2002-04-30 | 2005-08-11 | アルコン,インコーポレイテッド | 眼内圧の低下および緑内障性網膜症/眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子(ctgf)の活性および/または発現を調節するか、阻害するか、または調整する薬剤 |
US8415364B2 (en) * | 2003-11-26 | 2013-04-09 | Duke University | Method of preventing or treating glaucoma |
DE602005008935D1 (de) * | 2004-04-26 | 2008-09-25 | Alcon Inc | Statine zur behandlung von okularer hypertonie und glaukom |
WO2006040839A1 (ja) * | 2004-10-15 | 2006-04-20 | Advanced Medicine Research Institute | 眼疾患処置用点眼剤及びキット |
US20060094753A1 (en) * | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
US7803824B2 (en) * | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
EP2012815A4 (en) * | 2006-04-14 | 2009-12-09 | Massachusetts Inst Technology | IDENTIFICATION AND MODULATION OF MOLECULAR PATHWAYS THAT INDUCE THE PLASTICITY OF THE NERVOUS SYSTEM |
JP2010508306A (ja) * | 2006-10-31 | 2010-03-18 | アルコン リサーチ, リミテッド | 眼障害を治療するためのpai−1結合調節因子 |
-
2009
- 2009-04-09 US US12/421,456 patent/US20090202524A1/en not_active Abandoned
- 2009-04-10 KR KR1020107026494A patent/KR20100135953A/ko not_active Application Discontinuation
- 2009-04-10 CN CN2009801185568A patent/CN102046168A/zh active Pending
- 2009-04-10 JP JP2011506352A patent/JP2011518828A/ja active Pending
- 2009-04-10 WO PCT/US2009/040149 patent/WO2009131850A2/en active Application Filing
- 2009-04-10 EP EP09735222A patent/EP2296647A2/en not_active Withdrawn
- 2009-04-21 TW TW098113153A patent/TW200946113A/zh unknown
- 2009-04-22 AR ARP090101418A patent/AR071393A1/es not_active Application Discontinuation
- 2009-04-24 UY UY31786A patent/UY31786A1/es not_active Application Discontinuation
- 2009-04-24 CL CL2009000986A patent/CL2009000986A1/es unknown
-
2011
- 2011-01-14 US US13/006,984 patent/US20110105574A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2011518828A (ja) | 2011-06-30 |
TW200946113A (en) | 2009-11-16 |
UY31786A1 (es) | 2009-08-03 |
EP2296647A2 (en) | 2011-03-23 |
CN102046168A (zh) | 2011-05-04 |
US20110105574A1 (en) | 2011-05-05 |
WO2009131850A3 (en) | 2010-01-07 |
AR071393A1 (es) | 2010-06-16 |
WO2009131850A2 (en) | 2009-10-29 |
US20090202524A1 (en) | 2009-08-13 |
KR20100135953A (ko) | 2010-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
SV2008002958A (es) | Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania referencia cruzada ref. prd2592sv | |
GT200700034A (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40 | |
ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
CO6761350A2 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
ES2526606T3 (es) | Composición farmacéutica sólida que comprende amlodipina y losartán | |
RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
CR10165A (es) | "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión" | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
NI200800175A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias. | |
CL2007000345A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes. | |
CL2009000986A1 (es) | Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma | |
MX2007010295A (es) | Composiciones oftalmologicas novedosas y metodo para su uso. | |
CL2009001077A1 (es) | Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo. | |
CL2011003327A1 (es) | Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales. | |
BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
CL2012000611A1 (es) | Compuesto 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2- trifluoro-etoxi)-nicotinamida, util como agente que aumenta el colesterol hdl; proceso de obtencion del compuesto; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la aterosclerosis, dislipidemia, enfermedades cardiovasculares, entre otras. | |
AR054435A1 (es) | Agente para profilaxis o terapia contra la depresion o desorden de ansiedad | |
ES2723778T3 (es) | Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos |